Comparison Overview

Alembic Pharmaceuticals Limited

VS

Grifols

Alembic Pharmaceuticals Limited

Alembic Road, Vadodara, 390003, IN
Last Update: 2026-04-01
Between 750 and 799

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,168
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Grifols

Parc Empresarial Can Sant Joan, Sant Cugat del Vallès, 08174, ES
Last Update: 2026-04-04
Between 750 and 799

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,839
Subsidiaries: 4
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/alembic.jpeg
Alembic Pharmaceuticals Limited
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Alembic Pharmaceuticals Limited
100%
Compliance Rate
0/4 Standards Verified
Grifols
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Alembic Pharmaceuticals Limited in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Grifols in 2026.

Incident History — Alembic Pharmaceuticals Limited (X = Date, Y = Severity)

Alembic Pharmaceuticals Limited cyber incidents detection timeline including parent company and subsidiaries

Incident History — Grifols (X = Date, Y = Severity)

Grifols cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/alembic.jpeg
Alembic Pharmaceuticals Limited
Incidents

No Incident

https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
Incidents

No Incident

FAQ

Grifols company demonstrates a stronger AI Cybersecurity Score compared to Alembic Pharmaceuticals Limited company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Grifols company has disclosed a higher number of cyber incidents compared to Alembic Pharmaceuticals Limited company.

In the current year, Grifols company and Alembic Pharmaceuticals Limited company have not reported any cyber incidents.

Neither Grifols company nor Alembic Pharmaceuticals Limited company has reported experiencing a ransomware attack publicly.

Neither Grifols company nor Alembic Pharmaceuticals Limited company has reported experiencing a data breach publicly.

Neither Grifols company nor Alembic Pharmaceuticals Limited company has reported experiencing targeted cyberattacks publicly.

Neither Alembic Pharmaceuticals Limited company nor Grifols company has reported experiencing or disclosing vulnerabilities publicly.

Neither Alembic Pharmaceuticals Limited nor Grifols holds any compliance certifications.

Neither company holds any compliance certifications.

Grifols company has more subsidiaries worldwide compared to Alembic Pharmaceuticals Limited company.

Alembic Pharmaceuticals Limited company employs more people globally than Grifols company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Alembic Pharmaceuticals Limited nor Grifols holds SOC 2 Type 1 certification.

Neither Alembic Pharmaceuticals Limited nor Grifols holds SOC 2 Type 2 certification.

Neither Alembic Pharmaceuticals Limited nor Grifols holds ISO 27001 certification.

Neither Alembic Pharmaceuticals Limited nor Grifols holds PCI DSS certification.

Neither Alembic Pharmaceuticals Limited nor Grifols holds HIPAA certification.

Neither Alembic Pharmaceuticals Limited nor Grifols holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

nimiq/core-rs-albatross is a Rust implementation of the Nimiq Proof-of-Stake protocol based on the Albatross consensus algorithm. Prior to version 1.3.0, two peer-facing consensus request handlers assume that the history index is always available and call blockchain.history_store.history_index().unwrap() directly. That assumption is false by construction. HistoryStoreProxy::history_index() explicitly returns None for the valid HistoryStoreProxy::WithoutIndex state. when a full node is syncing or otherwise running without the history index, a remote peer can send RequestTransactionsProof or RequestTransactionReceiptsByAddress and trigger an Option::unwrap() panic on the request path. This issue has been patched in version 1.3.0.

Risk Information
cvss3
Base: 5.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L
Description

PraisonAI is a multi-agent teams system. Prior to version 1.5.95, FileTools.download_file() in praisonaiagents validates the destination path but performs no validation on the url parameter, passing it directly to httpx.stream() with follow_redirects=True. An attacker who controls the URL can reach any host accessible from the server including cloud metadata services and internal network services. This issue has been patched in version 1.5.95.

Risk Information
cvss3
Base: 8.6
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:N/A:N
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.97, OAuthManager.validate_token() returns True for any token not found in its internal store, which is empty by default. Any HTTP request to the MCP server with an arbitrary Bearer token is treated as authenticated, granting full access to all registered tools and agent capabilities. This issue has been patched in version 4.5.97.

Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.97, the PraisonAI Gateway server accepts WebSocket connections at /ws and serves agent topology at /info with no authentication. Any network client can connect, enumerate registered agents, and send arbitrary messages to agents and their tool sets. This issue has been patched in version 4.5.97.

Risk Information
cvss3
Base: 9.1
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N
Description

PraisonAI is a multi-agent teams system. Prior to version 4.5.90, MCPToolIndex.search_tools() compiles a caller-supplied string directly as a Python regular expression with no validation, sanitization, or timeout. A crafted regex causes catastrophic backtracking in the re engine, blocking the Python thread for hundreds of seconds and causing a complete service outage. This issue has been patched in version 4.5.90.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H